DCGI approves Covovax as booster dose

The DCGI’s approval came following recommendation by the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO).

212
DCGI CDSCO Regulator Drugs Controller General India
DCGI

Last Updated on December 31, 2023 by The Health Master

The Drug Controller General of India (DCGI) has approved market authorisation to COVID-19 vaccine Covovax as a heterologous booster dose for adults who have been administered two doses of Covishield or Covaxin, official sources said yesterday.

The DCGI’s approval came following recommendation by the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO).

Prakash Kumar Singh, Director, Government and Regulatory Affairs, Serum Institute of India (SII), had recently written to the DCGI for the approval of Covovax heterologous booster dose for those aged 18 years and older in view of the escalating COVID-19 pandemic situation in some countries, an official source had said.

The SEC of the CDSCO recently deliberated on the issue and had recommended for market authorisation of COVID jab Covovax as a heterologous booster dose for adults who have been administered two doses of Covishield or Covaxin, according to an official source.

The DCGI had approved Covovax for restricted use in emergency situations in adults on 28th December, 2021, in the 12- to 17-year-old age group on 9th March, 2022, and in children aged 7-11 years on 28th June last year subject to certain conditions.

Covovax is manufactured through technology transfer from Novavax. It has been approved by the European Medicines Agency (EMA) for conditional marketing authorisation.

It was granted Emergency Use Listing (EUL) by the World Health Organization (WHO) on 17th December, 2021.

In August 2020, the United States-based vaccine maker Novavax had announced a licence agreement with SII for the development and commercialization of NVX-CoV2373, its COVID-19 vaccine candidate in India and in low- and middle-income Countries (LMICs).

Covishield

Covaxin

Sputnik V

Modenra

DCGI gives nod to Phase-3 Clinical Trial of Covovax Vaccine

CDSCO Panel gives nod for FDC Tamsulosin + Solifenacin

CDSCO panel gives nod for Esomeprazole Dual Release Gastro resistant Tablets

CDSCO gives approval for this Anti-diabetic drug

CDSCO gives nod to Dapagliflozin Tablets

CDSCO approves 4 more Medical Device Testing Labs (MDTL)

USFDA gives tentative approval for Levomilnacipran extended-release capsules

IPC includes dissolution test in IP: Read details

NPPA fixes retail price of 12 formulations: January 2023

Drug recall: Epinephrine API recalled due to this reason

Deadline for Medical Colleges to submit PG Admissions info: NMC

NPPA revised Retail Price of 93 scheduled formulations: January 2023

Tramadol: 3 Pharmaceutical Companies under scanner

NABL suspends accreditation of 80 laboratories

List of approved FDCs (Fixed Dose Combinations) Updated

Latest Notifications regarding Pharmaceutical

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

YouTube Icon

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon

For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:

YouTube Icon

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

YouTube Icon

For informative videos on consumer awareness, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news